As technology becomes more integral to healthcare and valuations continue to climb, the margin for error is razor-thin when it comes to assessing the health of a target company’s technology, dealmakers say.
Category: NASDAQ:MDRX
As technology becomes more integral to healthcare and valuations continue to climb, the margin for error is razor-thin when it comes to assessing the health of a target company’s technology, dealmakers say.